Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.
详细描述
Ovarian cancer is the third most common gynecological malignancy，just less than endometrial cancer and cervical cancer. Because most patients with advanced ovarian cancer can not get the ideal tumor cell reduction surgery, and multi-drug resistance often emerges after repeated chemotherapy，recurrent and metastatic ovarian cancer has become one of the major diseases that threaten women's health. There is strongly necessary to explore effective therapeutic drugs and means to improve prognosis of these patients and improve the quality of life. The study，as a double blind clinical trial ,is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy regimens and failed. A total of 60 patients with performance status 0-2 were enrolled in this study, and were randomly divided into two groups--one group of 40 patients receiving apatinib，and another of 20 patients receiving placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •18 years to 70 years;
- •Had a histologically or cytologically confirmed diagnosis of epithelial ovarian cancer；
- •unfit for radical surgery and had received second-line chemotherapy，the disease still progressed or can not tolerate the chemotherapy;
- •Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1);
- •Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2;
- •Had a life expectancy of at least 12 weeks;
- •Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.5×the upper limit of normal (ULN), and b) ALT and AST≤2.5×the ULN (If liver metastases, serum creatine ≤ 1.5 x ULN);
- •Had not gastrointestinal diseases that lead to malabsorption or impact Drug absorption;
- •had good compliance;
- •Signed and dated informed consent.
排除标准
- •patients who had received anti-vascular therapy;
- •Allergic to any ingredients of Apatinib;
- •Participated in other drug clinical researchers within four weeks;
- •Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.)
- •Severe infection;
- •Patients with serious cardiovascular diseases,such as unstable angina, grade 3-4 heart dysfunction (NYHA Standard), congestive heart failure, poor-controlled arterial hypertension despite standard medical management;
- •Patients who received major surgical operations within 4 weeks before screening;
- •Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening;
- •Past or concurrent with other malignancies, except for cured skin basal cell carcinoma and cervical in situ cancer;
- •Have a history of psychiatric abuse and can not quit or have mental disorders.
研究组 & 干预措施
experimental group
apatinib 500 mg p.o. once daily
干预措施: apatinib (Drug)
control group
placebo p.o. once daily
干预措施: Placebos (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: approximately 2 years
Time from randomization until disease progression or death
次要结局
- Overall survival (OS)(approximately 2 years)
- disease control rate (DCR)(approximately 2 years)
- Objective response rate (ORR)(approximately 2 years)
- Quality of life (QoL)(approximately 2 years)
研究者
Mei Kai
associate senior doctor
Sichuan Cancer Hospital and Research Institute